Mobilizing haematopoietic progenitor cells (HPC) to repair the failing heart is a promising intervention to halt the progression of this deadly disease. We postulated that low doses of granulocyte colony stimulating factor (GCSF) could successfully mobilize HPC in advanced systolic heart failure and lead to beneficial effects. In a pilot study involving patients with advanced systolic heart failure, we established that a low dose (5 μg/kg/day for 5 days) of GCSF was sufficient to mobilize HPC into the peripheral blood in adequate numbers (>10 cells/μL) in spite of advanced heart failure and subject age. A striking observation was the significant elevation of plasma interleukin-10 levels in response to GCSF, without any change in tumour necrosis factor-α or interferon-γ levels. Left ventricular function improved significantly in subjects with ischaemic cardiomyopathy at 9 months after a single 5-day cycle of GCSF. Our results suggest the potential for improving left ventricular function in advanced systolic heart failure utilizing GCSF.
- Heart failure
- Stem cells
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine